Melanoma

Gene expression improves success of melanoma vaccine

Published in Vaccine Weekly, July 3rd, 2002

by Maria G. Essig, MS, ELS, senior medical writer - Expression of at least two of the five HLA class I antigens increased relapse-free survival rates of patients who receive an allogeneic tumor vaccine for treatment of malignant melanoma.

J.A. Sosman and colleagues at the Southwest Oncology Group, an organization involved in multicenter adult cancer clinical trials in the U.S. and Canada, performed a randomized, observation-control led clinical trial to investigate a reported link between expression of HLA class I antigens (HLA-A2, HLA-A28, HLA-B44, HLA-B45, and HLA-C3) and the success of an allogeneic cancer vaccine (Melacine, Corixa Corp., Seattle). The antigen group...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-07-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry